Friday, December 23, 2022 5:35:16 PM
AF says the rebuttal to JAMA is peer-reviewed - that is false, correct?
Another area of this rebuttal article that bears scrutiny. "And what about that presumed ‘noteworthy tails of long-term survival curves’? In the DCVax-L group 15.7% of patients were alive 48 months after randomization, whereas in the pivotal EORTC trial on chemo-irradiation with temozolomide without the stringent favorable prognosis patient selection and patients randomized prior to the start of radiotherapy, this was 12.1%."
www.nejm.org/doi/full/10.1056/nejmoa043330
If you look a the KM curves in the Stupp NEJM you notice that there are 4 in the "number at risk" at 36 months in the treatment group (radiation + temozolomide), so I'm thinking that 12% was a KM curve estimate. Subsequent studies casts doubt as well.
www.ncbi.nlm.nih.gov/pmc/articles/PMC7348058/#B1
In this publication of Stupp after a decade, they refer to the original result as 10%, not 12%, and show that subsequent studies have shown nowhere near that -- more like 2%.
Another area of this rebuttal article that bears scrutiny. "And what about that presumed ‘noteworthy tails of long-term survival curves’? In the DCVax-L group 15.7% of patients were alive 48 months after randomization, whereas in the pivotal EORTC trial on chemo-irradiation with temozolomide without the stringent favorable prognosis patient selection and patients randomized prior to the start of radiotherapy, this was 12.1%."
www.nejm.org/doi/full/10.1056/nejmoa043330
If you look a the KM curves in the Stupp NEJM you notice that there are 4 in the "number at risk" at 36 months in the treatment group (radiation + temozolomide), so I'm thinking that 12% was a KM curve estimate. Subsequent studies casts doubt as well.
www.ncbi.nlm.nih.gov/pmc/articles/PMC7348058/#B1
In this publication of Stupp after a decade, they refer to the original result as 10%, not 12%, and show that subsequent studies have shown nowhere near that -- more like 2%.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
